Anemia of cardiorenal syndrome

  • Peter A. McCullough
    Correspondence
    Correspondence: Peter A. McCullough, Baylor Heart and Vascular Institute, 621 N Hall St, Suite H030, Dallas, Texas 75226, USA.
    Affiliations
    Department of Medicine, Texas A & M College of Medicine, Baylor University Medical Center, Baylor Heart and Vascular Hospital, Baylor Heart and Vascular Institute, Dallas, Texas, USA
    Search for articles by this author
      Cardiorenal syndrome includes a spectrum of disorders of the kidneys and heart in which loss of function in one organ contributes to reduced function in the other organ. Cardiorenal syndrome is frequently complicated by comorbid anemia, which leads to reciprocal and progressive cardiac and renal deterioration. The triad of heart failure, chronic kidney disease (CKD), and anemia is termed cardiorenal anemia syndrome (CRAS). There are currently no evidence-based recommendations for managing patients with CRAS; however, the treatment of these patients is multifactorial. Not only must the anemia be controlled, but heart failure and kidney injury must be addressed, in addition to other comorbidities. Intravenous iron and erythropoiesis-stimulating agents are the mainstays of treatment for anemia of CKD, addressing both iron and erythropoiesis deficiencies. Since erythropoiesis-stimulating agent therapy can be associated with adverse outcomes at higher doses in patients with CKD and is not used in routine practice in patients with heart failure, treatment options for managing anemia in patients with CRAS are limited. Several new therapies, particularly the hypoxia-inducible factor–prolyl hydroxylase inhibitors, are currently under clinical development. The hypoxia-inducible factor–prolyl hydroxylase inhibitors have shown promising results for treating anemia of CKD in clinical trials and may confer benefits in patients with CRAS, potentially addressing some of the limitations of erythropoiesis-stimulating agents. Updated clinical practice guidelines for the screening and management of anemia in cardiorenal syndrome, in light of potential new therapies and clinical evidence, would improve the clinical outcomes of patients with this complex syndrome.

      Graphical Abstract

      Keywords

      To read this article in full you will need to make a payment
      ISN Member Login
      ISN Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rangaswami J.
        • Bhalla V.
        • Blair J.E.A.
        • et al.
        Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association.
        Circulation. 2019; 139: e840-e878
        • Cozzolino M.
        • Mangano M.
        • Stucchi A.
        • et al.
        Cardiovascular disease in dialysis patients.
        Nephrol Dial Transplant. 2018; 33: iii28-iii34
      1. 2018 USRDS Annual Data Report: Executive Summary.
        Am J Kidney Dis. 2019; 73: A9-A22
        • Yuan J.
        • Zou X.R.
        • Han S.P.
        • et al.
        Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE).
        BMC Nephrol. 2017; 18: 23
        • Go A.S.
        • Chertow G.M.
        • Fan D.
        • et al.
        Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
        N Engl J Med. 2004; 351: 1296-1305
        • Subbiah A.K.
        • Chhabra Y.K.
        • Mahajan S.
        Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup.
        Heart Asia. 2016; 8: 56-61
        • Al-Jarallah M.
        • Rajan R.
        • Al-Zakwani I.
        • et al.
        Incidence and impact of cardiorenal anaemia syndrome on all-cause mortality in acute heart failure patients stratified by left ventricular ejection fraction in the Middle East.
        ESC Heart Fail. 2019; 6: 103-110
        • Kim C.J.
        • Choi I.J.
        • Park H.J.
        • et al.
        Impact of cardiorenal anemia syndrome on short- and long-term clinical outcomes in patients hospitalized with heart failure.
        Cardiorenal Med. 2016; 6: 269-278
        • Mozaffarian D.
        • Benjamin E.J.
        • et al.
        • Writing Group Members
        Heart disease and stroke statistics-2016 update: a report from the American Heart Association.
        Circulation. 2016; 133: e38-e360
        • Smith G.L.
        • Lichtman J.H.
        • Bracken M.B.
        • et al.
        Renal impairment and outcomes in heart failure: systematic review and meta-analysis.
        J Am Coll Cardiol. 2006; 47: 1987-1996
        • Foley R.N.
        • Murray A.M.
        • Li S.
        • et al.
        Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999.
        J Am Soc Nephrol. 2005; 16: 489-495
        • He J.
        • Shlipak M.
        • Anderson A.
        • et al.
        Risk factors for heart failure in patients with chronic kidney disease: the CRIC (Chronic Renal Insufficiency Cohort) Study.
        J Am Heart Assoc. 2017; 6e005336
        • Parikh N.I.
        • Hwang S.-J.
        • Larson M.G.
        • et al.
        Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control.
        Arch Intern Med. 2006; 166: 1884
        • Kim-Mitsuyama S.
        • Soejima H.
        • Yasuda O.
        • et al.
        Anemia is an independent risk factor for cardiovascular and renal events in hypertensive outpatients with well-controlled blood pressure: a subgroup analysis of the ATTEMPT-CVD randomized trial.
        Hypertens Res. 2019; 42: 883-891
        • Silverberg D.S.
        • Wexler D.
        • Blum M.
        • et al.
        The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations.
        J Am Coll Cardiol. 2000; 35: 1737-1744
        • Ezekowitz J.A.
        • McAlister F.A.
        • Armstrong P.W.
        Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure.
        Circulation. 2003; 107: 223-225
        • Grote Beverborg N.
        • Klip I.T.
        • Meijers W.C.
        • et al.
        Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients.
        Circ Heart Fail. 2018; 11e004519
        • Nanas J.N.
        • Matsouka C.
        • Karageorgopoulos D.
        • et al.
        Etiology of anemia in patients with advanced heart failure.
        J Am Coll Cardiol. 2006; 48: 2485-2489
        • Silverberg D.S.
        • Wexler D.
        • Iaina A.
        • et al.
        Anemia, chronic renal disease and congestive heart failure - the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists.
        Int Urol Nephrol. 2006; 38: 295-310
        • Kosiborod M.
        • Smith G.L.
        • Radford M.J.
        • et al.
        The prognostic importance of anemia in patients with heart failure.
        Am J Med. 2003; 114: 112-119
        • Silverberg D.S.
        • Wexler D.
        • Iaina A.
        • et al.
        The role of anemia in the progression of congestive heart failure: is there a place for erythropoietin and intravenous iron?.
        Transfus Altern Transfus Med. 2008; 6: 26-37
        • Bock J.S.
        • Gottlieb S.S.
        Cardiorenal syndrome: new perspectives.
        Circulation. 2010; 121: 2592-2600
        • Ronco C.
        Cardiorenal syndromes: definition and classification.
        in: Contrib Nephrol. Vol 164. KARGER, Basel, Switzerland2010: 33-38
        • Yogasundaram H.
        • Chappell M.C.
        • Braam B.
        • et al.
        Cardiorenal syndrome and heart failure-challenges and opportunities.
        Can J Cardiol. 2019; 35: 1208-1219
        • McCullough P.A.
        • Tumlin J.A.
        • Szerlip H.
        • et al.
        Cardiorenal syndromes: advances in determining diagnosis, prognosis and therapy.
        J Cardiovasc Dis Diagn. 2015; 3: 1-28
        • Bonventre J.V.
        • Yang L.
        Cellular pathophysiology of ischemic acute kidney injury.
        J Clin Invest. 2011; 121: 4210-4221
        • Hu J.
        • Wang Y.
        • Geng X.
        • et al.
        Metabolic acidosis as a risk factor for the development of acute kidney injury and hospital mortality.
        Exp Ther Med. 2017; 13: 2362-2374
        • Sharfuddin A.A.
        • Molitoris B.A.
        Pathophysiology of ischemic acute kidney injury.
        Nat Rev Nephrol. 2011; 7: 189-200
        • Hartupee J.
        • Mann D.L.
        Neurohormonal activation in heart failure with reduced ejection fraction.
        Nat Rev Cardiol. 2017; 14: 30-38
        • Lymperopoulos A.
        • Rengo G.
        • Koch W.J.
        Adrenergic nervous system in heart failure: pathophysiology and therapy.
        Circ Res. 2013; 113: 739-753
        • McFarlane S.I.
        • Winer N.
        • Sowers J.R.
        Role of the natriuretic peptide system in cardiorenal protection.
        Arch Intern Med. 2003; 163: 2696-2704
        • Takimoto E.
        • Kass D.A.
        Role of oxidative stress in cardiac hypertrophy and remodeling.
        Hypertension. 2007; 49: 241-248
        • Mihai S.
        • Codrici E.
        • Popescu I.D.
        • et al.
        Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome.
        J Immunol Res. 2018; 2018: 2180373
        • Paulus W.J.
        • Tschope C.
        A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
        J Am Coll Cardiol. 2013; 62: 263-271
        • Palazzuoli A.
        • Antonelli G.
        • Nuti R.
        Anemia in cardio-renal syndrome: clinical impact and pathophysiologic mechanisms.
        Heart Fail Rev. 2011; 16: 603-607
        • Westenbrink B.D.
        • Visser F.W.
        • Voors A.A.
        • et al.
        Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well.
        Eur Heart J. 2006; 28: 166-171
        • Grote Beverborg N.
        • van Veldhuisen D.J.
        • van der Meer P.
        Anemia in heart failure: still relevant?.
        JACC Heart Fail. 2018; 6: 201-208
        • Jelkmann W.
        Proinflammatory cytokines lowering erythropoietin production.
        J Interferon Cytokine Res. 1998; 18: 555-559
        • Morceau F.
        • Dicato M.
        • Diederich M.
        Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis.
        Mediat Inflamm. 2009; 2009: 405016
        • van der Putten K.
        • Braam B.
        • Jie K.E.
        • et al.
        Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure.
        Nat Clin Pract Rev. 2008; 4: 47-57
        • Ajmal A.
        • Gessert C.E.
        • Johnson B.P.
        • et al.
        Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels.
        BMC Res Notes. 2013; 6: 443
        • Haase V.K.
        Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease.
        Kidney Int Suppl. 2021; 11: 8-25
        • Agarwal A.K.
        Iron metabolism and management: focus on chronic kidney disease.
        Kidney Int Suppl. 2021; 11: 46-57
        • Roger S.D.
        • Tio M.
        • Park H.C.
        • et al.
        Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: a systematic review and meta-analysis.
        Nephrology (Carlton). 2017; 22: 969-976
        • Zumbrennen-Bullough K.
        • Babitt J.L.
        The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients.
        Nephrol Dial Transplant. 2014; 29: 263-273
        • Charytan D.M.
        • Fishbane S.
        • Malyszko J.
        • et al.
        Cardiorenal syndrome and the role of the bone-mineral axis and anemia.
        Am J Kidney Dis. 2015; 66: 196-205
        • Tanaka M.
        • Komaba H.
        • Fukagawa M.
        Emerging association between parathyroid hormone and anemia in hemodialysis patients.
        Ther Apher Dial. 2018; 22: 242-245
        • Segall L.
        • Nistor I.
        • Covic A.
        Heart failure in patients with chronic kidney disease: a systematic integrative review.
        Biomed Res Int. 2014; 2014: 937398
        • Coe L.M.
        • Madathil S.V.
        • Casu C.
        • et al.
        FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis.
        J Biol Chem. 2014; 289: 9795-9810
        • Czaya B.
        • Faul C.
        The role of fibroblast growth factor 23 in inflammation and anemia.
        Int J Mol Sci. 2019; 20: 4195
        • Nuhu F.
        • Bhandari S.
        Oxidative stress and cardiovascular complications in chronic kidney disease, the impact of anaemia.
        Pharmaceuticals (Basel). 2018; 11: 103
        • Bissinger R.
        • Bhuyan A.A.M.
        • Qadri S.M.
        • et al.
        Oxidative stress, eryptosis and anemia: a pivotal mechanistic nexus in systemic diseases.
        FEBS J. 2019; 286: 826-854
        • El-Achkar T.M.
        • Ohmit S.E.
        • McCullough P.A.
        • et al.
        Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: the Kidney Early Evaluation Program.
        Kidney Int. 2005; 67: 1483-1488
        • Thomas M.C.
        • MacIsaac R.J.
        • Tsalamandris C.
        • et al.
        Unrecognized anemia in patients with diabetes: a cross-sectional survey.
        Diabetes Care. 2003; 26: 1164-1169
        • Deray G.
        • Heurtier A.
        • Grimaldi A.
        • et al.
        Anemia and diabetes.
        Am J Nephrol. 2004; 24: 522-526
        • Carrero J.J.
        • Barany P.
        • Yilmaz M.I.
        • et al.
        Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
        Nephrol Dial Transplant. 2012; 27: 709-715
        • Ferrucci L.
        • Maggio M.
        • Bandinelli S.
        • et al.
        Low testosterone levels and the risk of anemia in older men and women.
        Arch Intern Med. 2006; 166: 1380-1388
        • Lu K.J.
        • Kearney L.G.
        • Hare D.L.
        • et al.
        Cardiorenal anemia syndrome as a prognosticator for death in heart failure.
        Am J Cardiol. 2013; 111: 1187-1191
        • Pallangyo P.
        • Fredrick F.
        • Bhalia S.
        • et al.
        Cardiorenal anemia syndrome and survival among heart failure patients in Tanzania: a prospective cohort study.
        BMC Cardiovasc Disor. 2017; 17: 59
        • Scrutinio D.
        • Passantino A.
        • Santoro D.
        • et al.
        The cardiorenal anaemia syndrome in systolic heart failure: prevalence, clinical correlates, and long-term survival.
        Eur J Heart Fail. 2011; 13: 61-67
        • Belmar Vega L.
        • de Francisco A.
        • Albines Fiestas Z.
        • et al.
        Iron deficiency in patients with congestive heart failure: a medical practice that requires greater attention.
        Nefrología. 2016; 36: 249-254
        • Tang W.H.
        • Tong W.
        • Jain A.
        • et al.
        Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure.
        J Am Coll Cardiol. 2008; 51: 569-576
        • Minamisawa M.
        • Miura T.
        • Motoki H.
        • et al.
        Prognostic impact of cardio-renal-anemia syndrome in patients at risk for heart failure.
        Circulation. 2017; 136 (:A14876)
        • Bivol E.
        • Grib L.
        Psychosocial stress and quality of life in patients with type 2 cardiorenal syndrome.
        Arch Balkan Medical Union. 2019; 54: 147-154
        • Balakumaran K.
        • Patil A.
        • Marsh S.
        • et al.
        Evaluation of a guideline directed medical therapy titration program in patients with heart failure with reduced ejection fraction.
        Int J Cardiol Heart Vasc. 2019; 22: 1-5
        • Bhagat A.A.
        • Greene S.J.
        • Vaduganathan M.
        • et al.
        Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization.
        JACC Heart Fail. 2019; 7: 1-12
        • Clark A.
        • Kalra P.
        • Petrie M.
        • et al.
        FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis.
        Heart. 2019; 105: 904-910
        • Raebel M.A.
        Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: hyperkalemia with ACEI and ARB.
        Cardiovasc Ther. 2012; 30: e156-e166
        • Cole R.T.
        • Kalogeropoulos A.P.
        • Georgiopoulou V.V.
        • et al.
        Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions.
        Circulation. 2011; 123: 2414-2422
        • House A.A.
        • Wanner C.
        • Sarnak M.J.
        • et al.
        Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
        Kidney Int. 2019; 95: 1304-1317
        • Jhund P.S.
        • McMurray J.J.
        The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
        Heart. 2016; 102: 1342-1347
        • Koruth J.S.
        • Lala A.
        • Pinney S.
        • et al.
        The clinical use of ivabradine.
        J Am Coll Cardiol. 2017; 70: 1777-1784
        • Sica D.A.
        Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure.
        Methodist Debakey Cardiovasc J. 2015; 11: 235-239
        • Kluger A.Y.
        • Tecson K.M.
        • Lee A.Y.
        • et al.
        Class effects of SGLT2 inhibitors on cardiorenal outcomes.
        Cardiovasc Diabetol. 2019; 18: 99
        • McMurray J.J.V.
        • Solomon S.D.
        • Inzucchi S.E.
        • et al.
        Dapagliflozin in patients with heart failure and reduced ejection fraction.
        N Engl J Med. 2019; 381: 1995-2008
        • Maruyama T.
        • Takashima H.
        • Oguma H.
        • et al.
        Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease.
        Diabetes Technol Ther. 2019; 21: 713-720
        • Stefansson B.V.
        • Heerspink H.J.L.
        • Wheeler D.C.
        • et al.
        Correction of anemia by dapagliflozin in patients with type 2 diabetes.
        J Diabetes Complications. 2020; 34: 107729
        • Parikh R.H.
        • Seliger S.L.
        • Christenson R.
        • et al.
        Soluble ST2 for prediction of heart failure and cardiovascular death in an elderly, community-dwelling population.
        J Am Heart Assoc. 2016; 5e003188
        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • et al.
        2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.
        Circulation. 2017; 136: e137-e161
        • Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group
        KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.
        Kidney Int Suppl. 2013; 3: 1-150
        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • et al.
        2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2013; 128: 1810-1852
        • Lo K.B.
        • Gul F.
        • Ram P.
        • et al.
        The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis.
        Cardiorenal Med. 2020; 10: 1-10
        • Oliveros E.
        • Oni E.T.
        • Shahzad A.
        • et al.
        Benefits and risks of continuing angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and mineralocorticoid receptor antagonists during hospitalizations for acute heart failure.
        Cardiorenal Med. 2020; 10: 69-84
        • Singhania G.
        • Ejaz A.A.
        • McCullough P.A.
        • et al.
        Continuation of chronic heart failure therapies during heart failure hospitalization - a review.
        Rev Cardiovasc Med. 2019; 20: 111-120
        • Obi Y.
        • Kim T.
        • Kovesdy C.P.
        • et al.
        Current and potential therapeutic strategies for hemodynamic cardiorenal syndrome.
        Cardiorenal Med. 2016; 6: 83-98
        • Rangaswami J.
        • McCullough P.A.
        Heart failure in end-stage kidney disease: pathophysiology, diagnosis, and therapeutic strategies.
        Semin Nephrol. 2018; 38: 600-617
        • Ibrahim N.E.
        • Januzzi Jr., J.L.
        Established and emerging roles of biomarkers in heart failure.
        Circ Res. 2018; 123: 614-629
        • McCullough P.A.
        Practical experience using galectin-3 in heart failure.
        Clin Chem Lab Med. 2014; 52: 1425-1431
        • McCullough P.A.
        • Olobatoke A.
        • Vanhecke T.E.
        Galectin-3: a novel blood test for the evaluation and management of patients with heart failure.
        Rev Cardiovasc Med. 2011; 12: 200-210
        • Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group
        KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease.
        Kidney Int Suppl. 2012; 2: 279-335
        • Anker S.D.
        • Comin Colet J.
        • Filippatos G.
        • et al.
        Ferric carboxymaltose in patients with heart failure and iron deficiency.
        N Engl J Med. 2009; 361: 2436-2448
        • Ben-Assa E.
        • Shacham Y.
        • Shashar M.
        • et al.
        Target hemoglobin may be achieved with intravenous iron alone in anemic patients with cardiorenal syndrome: an observational study.
        Cardiorenal Med. 2015; 5: 246-253
        • Okonko D.O.
        • Grzeslo A.
        • Witkowski T.
        • et al.
        Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
        J Am Coll Cardiol. 2008; 51: 103-112
        • Ponikowski P.
        • van Veldhuisen D.J.
        • Comin-Colet J.
        • et al.
        Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger.
        Eur Heart J. 2015; 36: 657-668
        • Ponikowski P.
        • Voors A.A.
        • Anker S.D.
        • et al.
        2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
        Eur Heart J. 2016; 37: 2129-2200
        • Akaishi M.
        • Hiroe M.
        • Hada Y.
        • et al.
        Effect of anemia correction on left ventricular hypertrophy in patients with modestly high hemoglobin level and chronic kidney disease.
        J Cardiol. 2013; 62: 249-256
        • Silverberg D.
        The cardio-renal anaemia syndrome: does it exist?.
        Nephrol Dial Transpl. 2003; 18: viii7-viii12
        • Swedberg K.
        • Young J.B.
        • Anand I.S.
        • et al.
        Treatment of anemia with darbepoetin alfa in systolic heart failure.
        N Engl J Med. 2013; 368: 1210-1219
        • US Food and Drug Administration
        FDA drug safety communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease.
        (Available at:)
        • McCullough P.A.
        • Barnhart H.X.
        • Inrig J.K.
        • et al.
        Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
        Am J Nephrol. 2013; 37: 549-558
        • Eisenga M.F.
        • Emans M.E.
        • van der Putten K.
        • et al.
        Epoetin beta and C-terminal fibroblast growth factor 23 in patients with chronic heart failure and chronic kidney disease.
        J Am Heart Assoc. 2019; 8e011130
        • Jackevicius C.A.
        • Co M.J.
        • Warner A.L.
        Predictors of erythropoietin use in patients with cardiorenal anaemia syndrome.
        Int J Pharm Pract. 2015; 23: 199-204
        • Carson J.L.
        • Guyatt G.
        • Heddle N.M.
        • et al.
        Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage.
        JAMA. 2016; 316: 2025-2035
        • Carson J.L.
        • Stanworth S.J.
        • Alexander J.H.
        • et al.
        Clinical trials evaluating red blood cell transfusion thresholds: an updated systematic review and with additional focus on patients with cardiovascular disease.
        Am Heart J. 2018; 200: 96-101
        • Rao S.V.
        • Jollis J.G.
        • Harrington R.A.
        • et al.
        Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes.
        JAMA. 2004; 292: 1555-1562
        • Holst L.B.
        • Petersen M.W.
        • Haase N.
        • et al.
        Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis.
        BMJ. 2015; 350: h1354
        • Semenza G.L.
        Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology.
        Annu Rev Pathol. 2014; 9: 47-71
        • Haase V.H.
        • Chertow G.M.
        • Block G.A.
        • et al.
        Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents.
        Nephrol Dial Transplant. 2019; 34: 90-99
        • Kaplan J.M.
        • Sharma N.
        • Dikdan S.
        Hypoxia-inducible factor and its role in the management of anemia in chronic kidney disease.
        Int J Mol Sci. 2018; 19: 389
        • Provenzano R.
        • Besarab A.
        • Wright S.
        • et al.
        Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study.
        Am J Kidney Dis. 2016; 67: 912-924
        • Coyne D.W.
        • Goldsmith D.
        • Macdougall I.C.
        New options for the anemia of chronic kidney disease.
        Kidney Int Suppl (2011). 2017; 7: 157-163
        • Ghadge S.K.
        • Messner M.
        • Van Pham T.
        • et al.
        Prolyl-hydroxylase inhibition induces SDF-1 associated with increased CXCR4+/CD11b+ subpopulations and cardiac repair.
        J Mol Med (Berl). 2017; 95: 825-837
        • Young J.M.
        • Williams D.R.
        • Thompson A.A.R.
        Thin air, thick vessels: historical and current perspectives on hypoxic pulmonary hypertension.
        Front Med (Lausanne). 2019; 6: 93
        • Renders L.
        • Budde K.
        • Rosenberger C.
        • et al.
        First-in-human phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis.
        PLoS One. 2019; 14e0212023